West Nile Virus Infections Projected from Blood Donor Screening Data, United States, 2003
Michael P. Busch*† , David J. Wright‡, Brian Custer*, Leslie H. Tobler*, Susan L. Stramer§, Steven H. Kleinman*‡¶, Harry E. Prince#, Celso Bianco**, Gregory Foster§, Lyle R. Petersen††, George Nemo‡‡, and Simone A. Glynn‡
Author affiliations: *Blood Systems Research Institute, San Francisco, California, USA; †University of California, San Francisco, California, USA; ‡Westat, Rockville, Maryland, USA; §American Red Cross National Testing and Reference Laboratories, Gaithersburg, Maryland, USA; ¶University of British Columbia, Victoria, British Columbia, Canada; #Focus Diagnostics, Cypress, California, USA; **America's Blood Centers, Washington DC, USA; ††Centers for Disease Control and Prevention, Fort Collins, Colorado, USA; ‡‡National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA
Figure 3. West Nile virus minipool–nucleic acid amplification testing (MP-NAT) yield and immunoglobulin M (IgM) and IgG seroprevalence estimates for North Dakota, during and ≈8 months after the 2003 epidemic period.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.